Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Apr 15, 2026; 18(4): 117498
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.117498
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.117498
Association of carcinoembryonic antigen/carbohydrate antigen 19-9 with gastric cancer recurrence and chemotherapy toxicities
Yue Qi, Chen-Xuan Wu, Department of Medical Oncology, The Third Central Hospital of Tianjin, Tianjin 300170, China
Author contributions: Qi Y performed most of the experiments and wrote the manuscript; Wu CX designed the study and revised the manuscript.
Institutional review board statement: This study was approved by The Third Central Hospital of Tianjin (Tianjin, China).
Informed consent statement: All patients provided informed consent.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset are available from the corresponding author upon request.
Corresponding author: Chen-Xuan Wu, MD, Doctor, Department of Medical Oncology, The Third Central Hospital of Tianjin, No. 83 Jintang Road, Hedong District, Tianjin 300170, China. chenxuanw@aliyun.com
Received: December 9, 2025
Revised: January 8, 2026
Accepted: January 15, 2026
Published online: April 15, 2026
Processing time: 119 Days and 23 Hours
Revised: January 8, 2026
Accepted: January 15, 2026
Published online: April 15, 2026
Processing time: 119 Days and 23 Hours
Core Tip
Core Tip: This study included patients with stage II-III gastric cancer who received six cycles of the S-1 and oxaliplatin chemotherapy regimen postoperatively, measured serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels, and conducted a 1-year follow-up to explore the predictive value of these markers for cancer recurrence, chemotherapy-related gastrointestinal adverse reactions, and recurrence-free survival. CEA and CA19-9 could be reliable tools for guiding individualized treatment plans in patients with gastric cancer, highlighting their practical clinical value.